Deals
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Company enters next development phase with management expansion and implementation of a Strategic and Scientific Advisory Board
Heidelberg Pharma AG announces that it has successfully raised approximately EUR 14.4 million in gross proceeds through a private placement via an accelerated book building transaction.
FoRx Therapeutics AG, the biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways, announced the closing of a EUR 10 million seed financing led by M Ventures, Novartis Venture Fund and Omega Funds.
Despite booming commercial interest in plant-based and cultivated meat, funding for academic research lags behind, and the industries lack the open-access data required to overcome technical hurdles and scale up to become a viable part of the global food system.
Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint
4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, announces its investment in Redpin Therapeutics, Inc., a pioneering chemogenetics company developing drug-controlled gene therapies to address intractable diseases of the nervous system.
The delays, particularly in the regulatory review process, have caused the merger completion to be pushed back to the second half of this year.
Heidelberg Pharma AG published its financial results and annual report for fiscal year 2019 and its outlook for 2020.
Priority Review for BLA submission was granted by U.S. FDA for tafasitamab in combination with lenalidomide for relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) based on positive primary analysis data of L-MIND and Re-MIND studies
The company has nine drug candidates in human clinical trials.